Recurrent Implantation Failure After Euploid Transfer in a Couple With Advanced Maternal Age
A 39-year-old G0 woman and her 41-year-old partner present after three failed IVF cycles. Cycle 1: 6 oocytes, 2 day-3 embryos, no pregnancy. Cycle 2: 8 oocytes, 1 blastocyst, biochemical pregnancy. Cycle 3: 9 oocytes, 3 blastocysts, all aneuploid on PGT-A. Antral follicle count 7, AMH 0.9 ng/mL. Semen analysis: concentration 18 million/mL, motility 38%, morphology 3% (strict). She has regular cycles, normal TSH, normal prolactin, and a normal saline sonogram. She is requesting another cycle with PGT-A and asks whether she should also have intralipid infusions, empiric heparin, and endometrial receptivity testing (ERA) added.
1. Interpret the semen analysis and ovarian reserve data, and explain how they shape prognosis and counseling.
Read the worked answer
Semen analysis shows mild oligoasthenoteratozoospermia by WHO criteria (concentration 18 million/mL, motility 38%, morphology 3%). This is not severe enough to preclude IVF with ICSI if needed, but it warrants a repeat analysis and evaluation for reversible causes (varicocele, lifestyle, endocrine). It does not explain the aneuploidy pattern.
Ovarian reserve is diminished: AMH 0.9 ng/mL and AFC 7 indicate diminished ovarian reserve, predicting low oocyte yield and, at age 39, a high aneuploidy rate. The prior cycle with 3 blastocysts all aneuploid is consistent with age-related meiotic error, not an implantation problem per se.
Counseling: The dominant limiting factor is aneuploidy and oocyte quantity, not endometrial receptivity. Expected euploidy rate at 39 is roughly 30-40% per blastocyst; with 7-9 oocytes per cycle, many cycles yield zero euploid embryos. Realistic cumulative live birth counseling, discussion of donor oocytes, and consideration of whether further autologous cycles are worthwhile are central.
Judgment point: Distinguish "recurrent implantation failure" (which requires euploid embryos to define) from failure to achieve a euploid transfer.
2. Critique the request for intralipid, empiric heparin, and ERA in this specific context, and propose an evidence-based plan.
Read the worked answer
Intralipid: No high-quality evidence supports intralipid for implantation failure in unselected patients; it is not recommended outside research. Decline with explanation.
Empiric heparin/aspirin: Anticoagulation without a diagnosed thrombophilia or antiphospholipid syndrome is not indicated and carries bleeding risk. If she has a history of thrombosis or pregnancy loss meeting APS criteria, test antiphospholipid antibodies first; otherwise do not treat empirically.
ERA: The evidence for ERA in unselected patients is weak; a recent randomized trial did not show benefit in the general IVF population. It may be considered in select cases of recurrent failure with euploid embryos, but she has not yet had a euploid transfer. Ordering ERA now is premature and would consume a cycle's worth of time and cost without addressing the real bottleneck.
Evidence-based plan:
- Repeat semen analysis; urology referral if persistent.
- Optimize stimulation; discuss expected yield and cumulative prognosis.
- Proceed with PGT-A and transfer of a euploid embryo when available; this is the intervention most likely to change outcome.
- If she has a euploid transfer that fails (true RIF), then evaluate: uterine cavity (hysteroscopy), thrombophilia/APS panel, thyroid, and consider ERA in a shared decision-making framework.
- Discuss oocyte donation and adoption as parallel options given age and reserve.
The tested skill is resisting low-value add-ons and sequencing interventions to the actual diagnosis.